Abivax (ABVX) Liabilities and Shareholders Equity (2021 - 2026)

Abivax's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $640.6 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 264.78% year-over-year to $640.6 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 216.36% increase from a year earlier, with the FY2025 full-year figure at $680.2 million, up 206.26% from the prior year.
• Liabilities and Shareholders Equity fell to $640.6 million in Q1 2026 per ABVX's latest filing, from $680.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $762.3 million in Q3 2025 and bottomed at $77.1 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $306.4 million (2024), against an average of $372.1 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 356.58% in 2023 and tumbled 55.8% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $77.1 million in 2022, then soared by 356.58% to $351.9 million in 2023, then tumbled by 37.69% to $219.3 million in 2024, then soared by 210.2% to $680.2 million in 2025, then fell by 5.83% to $640.6 million in 2026.
• Per Business Quant, the three latest ABVX Liabilities and Shareholders Equity figures stand at $640.6 million (Q1 2026), $680.2 million (Q4 2025), and $762.3 million (Q3 2025).